Clinical Trial Update: A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations [Phase 2]

View source ↗

Summary

Phase II multicenter trial evaluating the combination of ibrutinib and venetoclax in relapsed/refractory chronic lymphocytic leukemia with adequate renal functi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission | Phase 2 | Status: ACTIVE_NOT_RECRUITING